Compound shows early positive effect in cell model

A new drug compound, developed by UK-based neuroscience company Nevrargenics, has shown early promise in laboratory cells and a pre-clinical model. While these early-stage results are interesting, it is still too early to say what the impact could be in humans.

Ellorarxine targets a process called retinoid signalling, which is involved in brain development and repair. More research is needed to say what effect, if any, the compound may have on neurodegenerative diseases, such as motor neuron disease (MND).

Nevrargenics published research towards the end of 2024, suggesting the drug demonstrated potentially positive effects on cells grown in the laboratory and a pre-clinical model. While this does look encouraging, there are no published data on safety or efficacy in humans.

The company has sought advice from the Medicines and Healthcare products Regulatory Agency (MHRA) about the protocol design of first in human clinical trials. We are in contact with Nevrargenics and will update the community once these trials are approved and underway.

As with all relevant developments, we will monitor this closely and keep you up to date.